imiquimod has been researched along with piperidines in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, T; Hashimoto, T; Sakai, K; Sanders, KM; Yosipovitch, G | 1 |
| Cataisson, C; Day, CP; Flowers, B; Fraser, E; Li, L; Sanchez, V; Yuspa, SH | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alotaibi, MR; Alqahtani, F; Alzahrani, KS; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Mahmood, HM; Nadeem, A | 1 |
| Banfi, G; Bridgewood, C; Damiani, G; Dunsmuir, R; El-Sherbiny, YM; Khan, A; Loughenbury, P; Malagoli, P; McGonagle, D; Millner, PA; Pigatto, PDM; Rao, A; Rowe, H; Russell, T; Sharif, K; Timothy, J; Vadakekolathu, J; Watad, A; Zhou, Q | 1 |
5 other study(ies) available for imiquimod and piperidines
| Article | Year |
|---|---|
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Topics: Animals; Antipruritics; Behavior, Animal; Disease Models, Animal; Imiquimod; Interleukin-22; Interleukin-23; Interleukins; Janus Kinase Inhibitors; Male; Mice, Inbred C57BL; Nerve Fibers; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Skin | 2019 |
Topical Application of a Dual ABC Transporter Substrate and NF-κB Inhibitor Blocks Multiple Sources of Cutaneous Inflammation in Mouse Skin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Humans; Imiquimod; Inflammation; Keratinocytes; Mice; NF-kappa B; Nicotinic Acids; Nitriles; Piperidines; Pyrrolidines; Skin; Skin Neoplasms | 2019 |
Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Dendritic Cells; Disease Models, Animal; Humans; Imiquimod; Immunity, Innate; Interleukin-17; Interleukin-23; Intraepithelial Lymphocytes; Male; Mice; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Signal Transduction; Skin | 2020 |
Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells.
Topics: Adenine; Animals; BALB 3T3 Cells; Dendritic Cells; Down-Regulation; Imiquimod; Inflammation Mediators; Male; Mice; Neutrophils; Oxidation-Reduction; Oxidative Stress; Peroxidase; Piperidines; Psoriasis; Signal Transduction; Skin | 2020 |
SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights.
Topics: Adjuvants, Immunologic; Adult; Aged; Arthritis, Psoriatic; Computational Biology; COVID-19; Cyclic Nucleotide Phosphodiesterases, Type 4; Dendritic Cells; Female; Gene Expression Regulation; Humans; Imiquimod; Interferon-alpha; Janus Kinases; Male; Middle Aged; NF-kappa B; Oligonucleotides; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Toll-Like Receptor 7; Toll-Like Receptor 9; Transcriptome; Tumor Necrosis Factor-alpha | 2021 |